Latest News

The International Diabetes Federation (IDF) annual meeting (December 2-6, 2013) and Immunology of Diabetes Society (IDS) annual meeting (December 7-11, 2013) in Australia will feature multiple talks on recent findings from the Immune Tolerance Network's ( ITN’s) portfolio of type 1 diabetes studies. Type 1 diabetes is a challenging disease where so far no therapeutic has been able to reverse or permanently halt the autoimmune attack on pancreatic β-cells. Clinical trials with immune modulating agents have had only modest clinical effects, but mechanistic data from these studies is contributing to the growing body of evidence about how cellular changes may relate to clinical outcomes, providing insights into how future treatments should be tailored.

Clinical data from the ITN’s ACCESS study (Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis) will be presented at two upcoming conferences. The ACCESS study examined whether the combination of abatacept (CTLA4-Ig) and cyclophosphamide is able to better induce tolerance compared to the Euro-Lupus regimen (low-dose pulse cyclophosphamide).

The Immune Tolerance Network (ITN) is retiring ITN BioShare. ITN’s inventory of clinical trial biospecimens is now available through ITN TrialShare. Now that ITN’s biorepository is accessible through TrialShare, all web traffic to BioShare will redirect to www.ITNTrialShare.org.

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Dr. Mark Rigby (Indiana University) are published today in The Lancet Diabetes & Endocrinology.

It is with great sadness that we report the passing of Lloyd Mayer, MD. As a small part of his being a fantastic colleague to all of us, Lloyd had been an active member of the Network Steering Committee since 2006 and the Protocol Chair for ITN047AI TAKE (“A study to determine The immunogenicity And oral tolerance to Keyhole limpet hemocyanin”).  Lloyd was also Professor and Co-Director of the Immunology Institute, the Dorothy and David Merksamer Professor of Medicine and Professor of Microbiology at the Mount Sinai Medical Center.

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) with the Immune Tolerance Network (ITN), were published in an article today in The Lancet Diabetes & Endocrinology. The study enrolled 58 new-onset type 1 diabetic subjects ages 12-35. The subjects were randomized 2:1 to antithymocyte globulin (ATG) treatment, which is currently licensed for the treatment of organ transplant rejection, or placebo. Patients in the ATG group received intravenous infusion over 4 consecutive days at the start of the study and were given mixed meal tolerance tests at 6 month intervals to measure insulin production throughout the study. The study was the first fully powered, placebo-controlled, multi-center study of ATG therapy in patients with new-onset type 1 diabetes.

In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org). Since then public usage of the system (not including ITN staff and collaborators) has increased dramatically with over 100 new users registering and 3000 total page hits by public users. While the RAVE study accounts for about one third of the study specific page hits, visits to other public studies have increased as well. ITN looks forward to continued expansion of data sharing through TrialShare and welcomes feedback from all of our users (trialsharesupport@immunetolerance.org).

In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org). The data published today come from the ITN’s RAVE study led by John Stone, MD (Massachusetts General Hospital) and Ulrich Specks, MD (Mayo Clinic). The researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxan, Genentech, Inc.) is as effective as the current standard of care regimen of drugs for remission induction and maintenance in patients with ANCA-associated Vasculitis (AAV). Rituximab has a shorter and simpler treatment course compared to standard therapy (cyclophosphamide), as well as an improved safety profile, thus offering significant treatment advancement for patients with AAV. This publication is the first to provide public access to the raw study data via direct links from the publication and its figures to the data sets in TrialShare. The accompanying editorial in NEJM highlights the utility of TrialShare in data sharing and transparency.

The Immune Tolerance Network’s (ITN’s) IMPACT Study, “Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children,” opened for enrollment today. This will be the first major study to examine whether oral immunotherapy can lead to durable, lasting tolerance to peanut among young peanut-allergic children. This study will be led by ITN investigator Wesley Burks, MD, Chair of the Department of Pediatrics at UNC Chapel Hill. Patients will be enrolled at UNC as well as at additional sites around the country including the University of Arkansas, Stanford University, Johns Hopkins Children’s Hospital and Mount Sinai Hospital.

Primary results from the Immune Tolerance Network’s AbATE study (Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes) were published online today in Diabetes. The Phase II AbATE study, led by Kevan Herold, MD (Yale University), tested two doses of anti-CD3 given one year apart in new onset type 1 diabetics compared to control. After 2 years, the anti-CD3-treated group showed significantly greater preservation of C-peptide compared to the control group (75% higher responses compared to control), meeting the study’s primary endpoint.